MEI Pharma, Inc. (MEIP): Price and Financial Metrics

MEI Pharma, Inc. (MEIP): $6.72

0.01 (-0.15%)

POWR Rating

Component Grades








Add MEIP to Watchlist
Sign Up

MEIP Price/Volume Stats

Current price $6.72 52-week high $7.97
Prev. close $6.73 52-week low $4.00
Day low $6.56 Volume 35,000
Day high $6.88 Avg. volume 55,451
50-day MA $6.76 Dividend yield N/A
200-day MA $6.31 Market Cap 44.78M

MEIP Stock Price Chart Interactive Chart >

MEIP Stock Summary

  • MEIP's current price/earnings ratio is 1, which is higher than only 0.63% of US stocks with positive earnings.
  • Over the past twelve months, MEIP has reported earnings growth of -176.84%, putting it ahead of just 7.67% of US stocks in our set.
  • Revenue growth over the past 12 months for MEI PHARMA INC comes in at 152.9%, a number that bests 96.41% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to MEI PHARMA INC, a group of peers worth examining would be XBIO, PALI, LUMO, TDUP, and OGEN.
  • Visit MEIP's SEC page to see the company's official filings. To visit the company's web site, go to

MEIP Valuation Summary

  • In comparison to the median Healthcare stock, MEIP's price/sales ratio is 78.38% lower, now standing at 0.4.
  • MEIP's EV/EBIT ratio has moved up 85.3 over the prior 242 months.

Below are key valuation metrics over time for MEIP.

Stock Date P/S P/B P/E EV/EBIT
MEIP 2023-11-20 0.4 0.5 0.9 1.1
MEIP 2023-11-17 0.4 0.5 1.0 1.2
MEIP 2023-11-16 0.4 0.5 1.0 1.2
MEIP 2023-11-15 0.5 0.6 1.3 1.5
MEIP 2023-11-14 0.5 0.6 1.2 1.4
MEIP 2023-11-13 0.5 0.6 1.2 1.4

MEIP Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -1462.91%.
  • Its 3 year net cashflow from operations growth rate is now at -77.22%.
  • Its year over year net cashflow from operations growth rate is now at -191.93%.
Over the past 34 months, MEIP's revenue has gone up $58,034,000.

The table below shows MEIP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 62.573 -61.511 -31.159
2022-09-30 41.67 -55.807 -53.568
2022-06-30 40.697 -48.746 -54.454
2022-03-31 36.737 -44.499 -46.769
2021-12-31 44.143 -43.19 -54.675
2021-09-30 35.088 -30.574 -60.363

MEIP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MEIP has a Quality Grade of C, ranking ahead of 61.23% of graded US stocks.
  • MEIP's asset turnover comes in at 0.131 -- ranking 236th of 682 Pharmaceutical Products stocks.
  • BLUE, BPMC, and NERV are the stocks whose asset turnover ratios are most correlated with MEIP.

The table below shows MEIP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.131 0.945 -34.832
2021-03-31 0.201 0.954 -23.189
2020-12-31 0.220 0.941 -19.061
2020-09-30 0.201 0.921 -34.437
2020-06-30 0.240 0.908 10.741
2020-03-31 0.051 0.275 3.585

MEIP Price Target

For more insight on analysts targets of MEIP, see our MEIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.67 Average Broker Recommendation 1.39 (Strong Buy)

MEI Pharma, Inc. (MEIP) Company Bio

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company was founded in 2000 and is based in San Diego, California.

MEIP Latest News Stream

Event/Time News Detail
Loading, please wait...

MEIP Latest Social Stream

Loading social stream, please wait...

View Full MEIP Social Stream

Latest MEIP News From Around the Web

Below are the latest news stories about MEI PHARMA INC that investors may wish to consider to help them evaluate MEIP as an investment opportunity.

11 Cheapest Stocks With Biggest Upside

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […]

Yahoo | November 27, 2023

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.

Yahoo | November 17, 2023

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Yahoo | November 10, 2023

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO, November 09, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events.

Yahoo | November 9, 2023

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Yahoo | November 9, 2023

Read More 'MEIP' Stories Here

MEIP Price Returns

1-mo -5.75%
3-mo 32.81%
6-mo -6.80%
1-year 42.98%
3-year -88.21%
5-year -86.34%
YTD 37.93%
2022 -90.88%
2021 1.14%
2020 6.45%
2019 -6.06%
2018 25.71%

Continue Researching MEIP

Want to see what other sources are saying about MEI Pharma Inc's financials and stock price? Try the links below:

MEI Pharma Inc (MEIP) Stock Price | Nasdaq
MEI Pharma Inc (MEIP) Stock Quote, History and News - Yahoo Finance
MEI Pharma Inc (MEIP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!